Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05488431 · ClinicalTrials.gov registry record · Phase 2
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
A Phase 2 study of HIV Infections and Cardiovascular Diseases, sponsored by Priscilla Hsue, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
- 3
- Study locations
NCT05488431 is a Phase 2 study of HIV Infections and Cardiovascular Diseases that is actively recruiting participants, run by Priscilla Hsue, MD. The registered enrollment target is 121 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (73% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT05488431, a Phase 2 study of HIV Infections and Cardiovascular Diseases, is actively recruiting participants, sponsored by Priscilla Hsue, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a randomized placebo-controlled study in treated and suppressed HIV-infected individuals aged ≥40 years with either known CVD or 1 CVD risk factor to study the effect of Bempedoic acid (BA) on safety, arterial inflammation as assessed by FDG-PET/CT, lipids, inflammation, immune activation, cardiometabolic indices, and non-calcified plaque (NCP) in the coronary arteries (assessed by coronary CT angiography, CCTA). This trial will be enrolled at UCSF and UCLA. Collaborators at Massachusetts General Hospital (MGH) will serve as the core facility for imaging.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Bempedoic acid
Study Locations (3)
California
- UCLA Center for Clinical AIDS Research and Education (CARE) - Los Angeles
- San Francisco General Hospital - San Francisco
Texas
- UT Health Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2028-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05488431
The ClinicalTrials.gov registry entry for NCT05488431 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (73% lower). The listed sponsor is Priscilla Hsue, MD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05488431 reports 3 study locations spanning 2 distinct geographic areas - top geographies include California, Texas.
Frequently Asked Questions
What is clinical trial NCT05488431 about?
NCT05488431 is a clinical study titled "Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)". This is a randomized placebo-controlled study in treated and suppressed HIV-infected individuals aged ≥40 years with either known CVD or 1 CVD risk factor to study the effect of Bempedoic acid (BA) on safety, arterial inflammation as assessed by FDG-PET/CT, lipids, inflammation, immune activation, c...
What is the current status of trial NCT05488431?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2023-03-01. Estimated completion is 2028-03-01.
What conditions does trial NCT05488431 study?
This clinical trial studies the following conditions: HIV Infections, Cardiovascular Diseases, Atherosclerosis, Dyslipidemias.
What interventions are being tested in trial NCT05488431?
The interventions under investigation include: Placebo (OTHER), Bempedoic acid (DRUG).
Who is sponsoring clinical trial NCT05488431?
This trial is sponsored by Priscilla Hsue, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05488431 being conducted?
This trial has 3 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
-
Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.